Response to, "Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond"
Radiother Oncol
.
2021 Jan:154:e17.
doi: 10.1016/j.radonc.2020.07.011.
Epub 2020 Jul 13.
Authors
Leila T Tchelebi
1
,
Karyn Goodman
2
Affiliations
1
Department of Radiation Oncology, Penn State College of Medicine, Hershey, USA. Electronic address: ltchelebi@pennstatehealth.psu.edu.
2
Department of Radiation Oncology, The Mount Sinai Hospital, New York, USA.
PMID:
32673775
PMCID:
PMC7357500
DOI:
10.1016/j.radonc.2020.07.011
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19*
Chemoradiotherapy
Esophageal Neoplasms* / drug therapy
Humans
Neoadjuvant Therapy
SARS-CoV-2